Monoclonal Antibody Therapeutics
•152 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (152)
| Company | Market Cap | Price |
|---|---|---|
|
IPHA
Innate Pharma S.A.
Lacutamab and monalizumab are monoclonal antibodies, aligning with Monoclonal Antibody Therapeutics.
|
$153.03M |
$1.88
+1.08%
|
|
CHRS
Coherus Oncology, Inc.
LOQTORZI is a differentiated PD-1 monoclonal antibody and commercial oncology product, aligning with Monoclonal Antibody Therapeutics.
|
$152.26M |
$1.31
+2.34%
|
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
CRB-601 is a monoclonal antibody therapeutic, placing Corbus in the monoclonal antibody therapeutics space.
|
$145.59M |
$11.90
+4.71%
|
|
AGEN
Agenus Inc.
Botensilimab (BOT) and balstilimab (BAL) are monoclonal antibody therapeutics targeting CTLA-4 and PD-1 pathways.
|
$144.98M |
$4.57
+4.34%
|
|
CGEN
Compugen Ltd.
COM701 and GS-0321 are monoclonal antibody therapeutics in development, aligning with Monoclonal Antibody Therapeutics.
|
$142.36M |
$1.59
|
|
SRZN
Surrozen, Inc.
Company develops monoclonal antibody therapeutics targeting tissue-specific Wnt signaling.
|
$140.94M |
$16.46
+2.84%
|
|
ALEC
Alector, Inc.
Latozinemab and AL101 are monoclonal antibody therapeutics in the pipeline.
|
$136.64M |
$1.34
+5.08%
|
|
TNXP
Tonix Pharmaceuticals Holding Corp.
TNX-1500 is a monoclonal antibody therapeutic, a core biologic drug candidate developed by Tonix.
|
$132.19M |
$15.06
+7.00%
|
|
ABOS
Acumen Pharmaceuticals, Inc.
Sabirnetug is a recombinant humanized IgG2 monoclonal antibody targeting soluble AßOs.
|
$118.12M |
$1.96
+1.03%
|
|
RANI
Rani Therapeutics Holdings, Inc.
RT-111 involves oral delivery of monoclonal antibodies, aligning with monoclonal antibody therapeutics.
|
$116.43M |
$1.64
+1.86%
|
|
LPTX
Leap Therapeutics, Inc.
Its lead assets, sirexatamab (DKN-01) and FL-501, are monoclonal antibodies targeting cancer pathways.
|
$116.14M |
$2.04
+367.43%
|
|
STTK
Shattuck Labs, Inc.
SL-325 is a monoclonal antibody targeting DR3, making Monoclonal Antibody Therapeutics a direct product category.
|
$102.03M |
$2.13
+6.22%
|
|
CNTX
Context Therapeutics Inc.
CTX's products are therapeutic antibodies (monoclonal antibody therapeutics) used for cancer.
|
$101.37M |
$1.14
+1.79%
|
|
PLRX
Pliant Therapeutics, Inc.
PLN-101325 is a monoclonal antibody agonist targeting integrin α7β1, representing a direct antibody therapeutic program.
|
$96.99M |
$1.58
+0.64%
|
|
ADAG
Adagene Inc.
Core focus on monoclonal antibody therapeutics (ADG126 and related SAFEbody-based antibodies).
|
$93.85M |
$2.12
+6.53%
|
|
MGNX
MacroGenics, Inc.
MacroGenics has approved monoclonal antibody assets (MARGENZA, ZYNYZ, TZIELD) and focuses on monoclonal antibody therapeutics.
|
$93.54M |
$1.48
+1.72%
|
|
ELDN
Eledon Pharmaceuticals, Inc.
Tegoprubart is an IgG1 monoclonal antibody therapeutic targeting CD40L.
|
$92.82M |
$1.54
-7.78%
|
|
FBIO
Fortress Biotech, Inc.
UNLOXCYT (cosibelimab-ipdl) asset involves a monoclonal antibody, fitting Monoclonal Antibody Therapeutics.
|
$82.12M |
$2.77
+2.79%
|
|
IGMS
IGM Biosciences, Inc.
IGMS's engineered antibodies are monoclonal antibody therapeutics, a core product category.
|
$76.35M |
$1.27
|
|
STRO
Sutro Biopharma, Inc.
ADC therapies are a form of monoclonal antibody–based therapeutics, aligning with Sutro's antibody-drug conjugate products.
|
$75.14M |
$0.89
+3.53%
|
|
IFRX
InflaRx N.V.
Vilobelimab is an anti-C5a monoclonal antibody, making InflaRx's core product line Monoclonal Antibody Therapeutics.
|
$70.07M |
$1.19
+0.42%
|
|
XBIT
XBiotech Inc.
Core products are monoclonal antibody therapeutics derived from the True Human platform.
|
$69.51M |
$2.29
-2.34%
|
|
EQ
Equillium, Inc.
Itolizumab is a monoclonal antibody therapeutic, mapping to Monoclonal Antibody Therapeutics.
|
$60.69M |
$1.01
+8.63%
|
|
OTLK
Outlook Therapeutics, Inc.
Bevacizumab is a monoclonal antibody; ONS-5010 is a monoclonal antibody therapeutic formulated for ophthalmic use.
|
$56.39M |
$1.69
+5.62%
|
|
ANL
Adlai Nortye Ltd.
ANL’s antibody-based therapeutics position the company within Monoclonal Antibody Therapeutics as a related category.
|
$50.87M |
$1.37
-1.44%
|
|
BCAB
BioAtla, Inc.
Evalstotug is a CAB-CTLA-4 antibody, a monoclonal antibody therapeutic.
|
$49.95M |
$0.85
+2.93%
|
|
LVTX
LAVA Therapeutics N.V.
The company focuses on antibody-based therapeutics (monoclonal antibody–type products) for cancer via its Gammabody platform.
|
$45.76M |
$1.65
-5.17%
|
|
ATNM
Actinium Pharmaceuticals, Inc.
Actinium employs monoclonal antibodies (e.g., lintuzumab) as targeting components in its antibody-based radiotherapies.
|
$45.23M |
$1.46
+4.29%
|
|
SKYE
Skye Bioscience, Inc.
Nimacimab is a monoclonal antibody therapeutic targeting CB1, making Monoclonal Antibody Therapeutics the direct product category.
|
$40.59M |
$1.31
+2.73%
|
|
XLO
Xilio Therapeutics, Inc.
Vilastobart is an anti-CTLA-4 monoclonal antibody, aligning with Monoclonal Antibody Therapeutics.
|
$38.88M |
$0.75
-0.25%
|
|
NXTC
NextCure, Inc.
ADCs are based on monoclonal antibodies delivering cytotoxic payloads, fitting the Monoclonal Antibody Therapeutics category.
|
$36.48M |
$13.89
-0.43%
|
|
FGEN
FibroGen, Inc.
FG-3246 utilizes a monoclonal antibody payload (YS5), aligning with Monoclonal Antibody Therapeutics.
|
$35.77M |
$8.41
-1.75%
|
|
DYAI
Dyadic International, Inc.
C1 platform has been used to produce monoclonal antibodies targeting RSV and malaria in legacy biopharma programs.
|
$33.84M |
$0.95
-0.46%
|
|
RADX
Radiopharm Theranostics Limited
Antibody-based therapeutics (PSA-mAb and B7-H3 mAb) used in radiopharmaceutical contexts.
|
$30.63M |
$4.75
+1.71%
|
|
JSPR
Jasper Therapeutics, Inc.
Core product briquilimab is a monoclonal antibody therapeutic, fitting Monoclonal Antibody Therapeutics.
|
$28.36M |
$1.75
-0.29%
|
|
IKNA
Ikena Oncology, Inc.
IMG-007 is a monoclonal antibody therapeutic, placing the company in the Monoclonal Antibody Therapeutics category.
|
$27.79M |
$7.11
|
|
RLYB
Rallybio Corporation
Lead programs are monoclonal antibody therapeutics (RLYB116 and RLYB332).
|
$26.87M |
$0.65
-0.32%
|
|
LIMN
Liminatus Pharma, Inc. Class A Common Stock
Monoclonal antibody therapeutics tag reflects LIMN's lead anti-CD47 antibody program as a targeted biologic for cancer.
|
$25.39M |
$0.99
+11.85%
|
|
QTTB
Q32 Bio Inc.
Bempikibart is a fully human monoclonal antibody targeting IL-7Rα, a core monoclonal antibody therapeutic category.
|
$25.13M |
$2.08
+2.46%
|
|
IBIO
iBio, Inc.
IBIO is developing monoclonal antibody therapeutics (e.g., IBIO-101, IBIO-600, Activin E antibodies).
|
$23.59M |
$1.21
+2.99%
|
|
AKTX
Akari Therapeutics, Plc
ADC uses monoclonal antibodies, aligning with monoclonal antibody therapeutics.
|
$22.08M |
$0.46
+3.45%
|
|
CASI
CASI Pharmaceuticals, Inc.
CID-103 is a monoclonal antibody therapeutic, a core product class for the company.
|
$15.45M |
$1.04
-7.96%
|
|
KAPA
Kairos Pharma, Ltd.
ENV-105 is a monoclonal antibody therapeutic (CD105 antagonist) in development.
|
$15.35M |
$0.74
+1.39%
|
|
PMN
ProMIS Neurosciences, Inc.
PMN310 is a monoclonal antibody therapeutic targeting toxic amyloid-beta oligomers for Alzheimer's disease.
|
$15.00M |
$0.29
-7.98%
|
|
EDSA
Edesa Biotech, Inc.
EB06 is an anti-CXCL10 monoclonal antibody therapeutic directly developed by Edesa for vitiligo, representing a direct monoclonal antibody product.
|
$12.01M |
$1.72
+2.38%
|
|
THAR
Tharimmune, Inc.
THAR directly develops monoclonal antibody therapeutics (e.g., TH023 and IO assets HS1940/HS3215), fitting Monoclonal Antibody Therapeutics.
|
$11.87M |
$2.58
+2.79%
|
|
SNSE
Sensei Biotherapeutics, Inc.
Solnerstotug is a monoclonal antibody therapeutic targeting VISTA, aligning with Monoclonal Antibody Therapeutics.
|
$10.66M |
$8.75
+1.74%
|
|
IMRN
Immuron Limited
Antibody-based therapeutics (monoclonal antibody category) reflects Immuron's antibody-focused therapy approach.
|
$9.97M |
$1.76
+1.44%
|
|
BOLT
Bolt Biotherapeutics, Inc.
The company develops monoclonal antibody therapeutics (e.g., BDC-3042) as part of its ISAC platform.
|
$9.50M |
$5.08
+0.30%
|
|
BCTX
BriaCell Therapeutics Corp.
BriaPro's high-affinity B7-H3 antibodies represent monoclonal antibody therapeutics.
|
$6.97M |
$10.38
+7.56%
|
|
HCWB
HCW Biologics Inc.
Second-generation pembrolizumab-based constructs and antibody-based ICIs fit Monoclonal Antibody Therapeutics.
|
$4.20M |
$1.96
+2.08%
|
|
ZVSA
ZyVersa Therapeutics, Inc.
IC 100 is a humanized monoclonal IgG4 antibody targeting ASC, classifiable as Monoclonal Antibody Therapeutics.
|
$378551 |
$0.14
|
Showing page 2 of 2 (152 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
